Currently, ASBT inhibitors have shown therapeutic potential for treating cholestasis, hyperlipidemia, type-II diabetes and NASH in preclinical and clinical studies12,13,57, but the mechanisms of action are still incompletely understood. This evidence concerns the gene SLC10A2 and metabolic dysfunction-associated steatohepatitis.